Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix

Clear cell carcinoma (CCC) of the cervix (cCCC) is a rare and aggressive type of human papillomavirus (HPV)‐negative cervical cancer with limited effective treatment options for recurrent or metastatic disease. Historically, CCCs of the lower genital tract were associated with in utero diethylstilbestrol exposure; however, the genetic landscape of sporadic cCCCs remains unknown. Here we sought to define the molecular underpinning of cCCCs. Using a combination of whole‐exome, targeted capture, and RNA‐sequencing, we identified pathogenic genetic alterations in the Hippo signaling pathway in 50% (10/20) of cCCCs, including recurrent WWTR1 S89W somatic mutations in 40% (4/10) of the cases harboring mutations in the Hippo pathway. Irrespective of the presence or absence of Hippo pathway genetic alterations, however, all primary cCCCs analyzed in this study (n = 20) harbored features of Hippo pathway deregulation at the transcriptomic and protein levels. In vitro functional analysis revealed that expression of the WWTR1 S89W mutation leads to reduced binding of TAZ to 14‐3‐3, promoting constitutive nuclear translocation of TAZ and Hippo pathway repression. WWTR1 S89W expression was found to lead to acquisition of oncogenic behavior, including increased proliferation, migration, and colony formation in vitro as well as increased tumorigenesis in vivo, which could be reversed by targeted inhibition of the TAZ/YAP1 complex with verteporfin. Finally, xenografts expressing WWTR1 S89W displayed a shift in tumor phenotype, becoming more infiltrative as well as less differentiated, and were found to be composed of cells with conspicuous cytoplasmic clearing as compared to controls. Our results demonstrate that Hippo pathway alterations are likely drivers of cCCCs and likely contribute to the clear cell phenotype. Therapies targeting this pathway may constitute a new class of treatment for these rare, aggressive tumors. © 2022 The Pathological Society of Great Britain and Ireland.

[1]  Jonghwan Kim,et al.  Context-dependent roles of YAP/TAZ in stem cell fates and cancer , 2021, Cellular and Molecular Life Sciences.

[2]  D. Bowtell,et al.  Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer , 2020, Cancer Research.

[3]  A. Zaravinos,et al.  Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers , 2020, PLoS pathogens.

[4]  O. Peralta-Zaragoza,et al.  MiR-23b-3p reduces the proliferation, migration and invasion of cervical cancer cell lines via the reduction of c-Met expression , 2020, Scientific Reports.

[5]  J. Reis-Filho,et al.  Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary , 2020, Nature Communications.

[6]  Kay J. Park Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification , 2019, Histopathology.

[7]  C. G. Hansen,et al.  The Hippo Pathway, YAP/TAZ, and the Plasma Membrane. , 2019, Trends in cell biology.

[8]  Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 145(2019) 129–135] , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  O. Mariani,et al.  The Genomic Landscape of Mucinous Breast Cancer. , 2019, Journal of the National Cancer Institute.

[10]  I. Petersen,et al.  SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY , 2019, Modern Pathology.

[11]  R. Soslow,et al.  Recent advances in invasive adenocarcinoma of the cervix , 2019, Virchows Archiv.

[12]  W. Hong,et al.  Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis , 2019, Front. Cell Dev. Biol..

[13]  J. Berek,et al.  Revised FIGO staging for carcinoma of the cervix uteri , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  Ronglai Shen,et al.  Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. , 2018, Cancer cell.

[15]  Leng Han,et al.  Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer , 2018, Cell reports.

[16]  I. Ellis,et al.  Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors , 2018, Nature Communications.

[17]  I. Ellis,et al.  Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas , 2018, Nature Communications.

[18]  D. Huo,et al.  Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. , 2018, The New England journal of medicine.

[19]  Ashton C. Berger,et al.  A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. , 2018, Cancer cell.

[20]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[21]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[22]  S. Bae,et al.  DNA binding partners of YAP/TAZ , 2018, BMB reports.

[23]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.

[24]  Xiaolong Yang,et al.  TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1 , 2017, Oncotarget.

[25]  J. Li,et al.  Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP‐TEAD complex , 2017, Cancer science.

[26]  Shuangyue Liu,et al.  LATS1 suppresses proliferation and invasion of cervical cancer , 2017, Molecular medicine reports.

[27]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[28]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[29]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[30]  J. Shipley,et al.  The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma , 2016, The Journal of pathology.

[31]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[32]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[33]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[34]  M. Sudol,et al.  TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells* , 2015, The Journal of Biological Chemistry.

[35]  A. A. Stepanenko,et al.  HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. , 2015, Gene.

[36]  H. Nojima,et al.  Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP , 2015, Genes & development.

[37]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[38]  M. Fukayama,et al.  HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy , 2015, BMC Cancer.

[39]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[40]  Simion I. Chiosea,et al.  Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands , 2014, Nature Genetics.

[41]  T. Hasan,et al.  Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer , 2014, British Journal of Cancer.

[42]  Mikhail Shugay,et al.  Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions , 2013, Bioinform..

[43]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[44]  G. Lou,et al.  Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma: The Differential Effects Based on Histotypes , 2013, International Journal of Gynecologic Cancer.

[45]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[46]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[47]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[48]  Bin Zhao,et al.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.

[49]  B. Weigelt,et al.  PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.

[50]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[51]  Nicola Elvassore,et al.  Role of YAP/TAZ in mechanotransduction , 2011, Nature.

[52]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[53]  J. Reynolds,et al.  Nanodrug applications in photodynamic therapy. , 2011, Photodiagnosis and photodynamic therapy.

[54]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[55]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[56]  Zhengyu Zha,et al.  TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.

[57]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[58]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[59]  B. Edgar,et al.  Filling out the Hippo pathway , 2007, Nature Reviews Molecular Cell Biology.

[60]  Jianbin Huang,et al.  The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP , 2005, Cell.

[61]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[62]  J. Barrett,et al.  Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero , 1996, Cancer.

[63]  Diethylstilbestrol Contraindicated Selected item from the FDA drug bulletin-november 1971: diethylstilbestrol contraindicated in pregnancy. , 1972, California medicine.

[64]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.